Aurion Resources Valuation
Is 8RA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8RA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 8RA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 8RA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8RA?
Key metric: As 8RA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 8RA's PB Ratio? | |
|---|---|
| PB Ratio | 1.3x |
| Book | CA$69.97m |
| Market Cap | CA$92.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -21.7x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 8RA's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.3x | ||
M0LY Greenland Resources | 41.6x | n/a | €66.4m |
BNN BRAIN Biotech | 4.3x | 71.5% | €69.9m |
EIS Eisen- und Hüttenwerke | 2.3x | n/a | €202.4m |
NTG Nabaltec | 0.8x | 4.3% | €123.2m |
8RA Aurion Resources | 1.3x | -29.3% | €92.3m |
Price-To-Book vs Peers: 8RA is good value based on its Price-To-Book Ratio (1.3x) compared to the peer average (12.3x).
Price to Book Ratio vs Industry
How does 8RA's PB Ratio compare vs other companies in the European Metals and Mining Industry?
| 22 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 22 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 8RA is expensive based on its Price-To-Book Ratio (1.3x) compared to the European Metals and Mining industry average (0.9x).
Price to Book Ratio vs Fair Ratio
What is 8RA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 1.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 8RA's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.40 | €0.68 +72.5% | 12.1% | €0.79 | €0.60 | n/a | 3 |
| Nov ’25 | €0.41 | €0.68 +65.4% | 12.1% | €0.79 | €0.60 | n/a | 3 |
| Oct ’25 | €0.41 | €0.71 +71.6% | 8.8% | €0.80 | €0.67 | n/a | 3 |
| Sep ’25 | €0.34 | €0.79 +129.3% | 20.2% | €1.02 | €0.68 | n/a | 3 |
| Aug ’25 | €0.34 | €0.79 +129.3% | 20.2% | €1.02 | €0.68 | n/a | 3 |
| Jul ’25 | €0.38 | €0.79 +109.3% | 20.2% | €1.02 | €0.68 | n/a | 3 |
| Jun ’25 | €0.42 | €0.79 +86.6% | 20.2% | €1.02 | €0.68 | n/a | 3 |
| May ’25 | €0.43 | €0.79 +82.5% | 20.2% | €1.02 | €0.68 | n/a | 3 |
| Apr ’25 | €0.40 | €0.79 +98.5% | 20.2% | €1.02 | €0.68 | n/a | 3 |
| Mar ’25 | €0.31 | €0.78 +155.5% | 21.6% | €1.02 | €0.65 | n/a | 3 |
| Feb ’25 | €0.31 | €0.79 +157.1% | 21.6% | €1.03 | €0.65 | n/a | 3 |
| Jan ’25 | €0.31 | €0.78 +156.0% | 21.6% | €1.02 | €0.65 | n/a | 3 |
| Dec ’24 | €0.29 | €0.78 +172.0% | 21.6% | €1.02 | €0.65 | €0.39 | 3 |
| Nov ’24 | €0.31 | €0.79 +152.4% | 21.6% | €1.03 | €0.65 | €0.41 | 3 |
| Oct ’24 | €0.34 | €0.82 +144.1% | 18.0% | €1.03 | €0.69 | €0.41 | 3 |
| Sep ’24 | €0.33 | €0.81 +144.9% | 18.0% | €1.02 | €0.68 | €0.34 | 3 |
| Aug ’24 | €0.38 | €0.84 +118.5% | 18.0% | €1.05 | €0.70 | €0.34 | 3 |
| Jul ’24 | €0.39 | €0.84 +112.9% | 18.0% | €1.05 | €0.70 | €0.38 | 3 |
| Jun ’24 | €0.44 | €0.82 +85.5% | 18.0% | €1.02 | €0.68 | €0.42 | 3 |
| May ’24 | €0.51 | €0.82 +61.7% | 18.0% | €1.02 | €0.68 | €0.43 | 3 |
| Apr ’24 | €0.47 | €0.83 +77.3% | 18.0% | €1.04 | €0.70 | €0.40 | 3 |
| Mar ’24 | €0.37 | €0.83 +124.4% | 18.0% | €1.04 | €0.70 | €0.31 | 3 |
| Feb ’24 | €0.40 | €0.82 +106.7% | 18.0% | €1.03 | €0.69 | €0.31 | 3 |
| Jan ’24 | €0.36 | €0.91 +154.1% | 18.0% | €1.14 | €0.76 | €0.31 | 3 |
| Dec ’23 | €0.41 | €0.91 +123.0% | 18.0% | €1.14 | €0.76 | €0.29 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.